VEGFA and hepatocellular carcinoma: Besides surgery, liver transplantation, or loco-regional approaches, options for HCC treatment include first line (VEGF inhibitors) and second line (immune check-point inhibitors, ICI) medications, but mortality remains high, with an average 5-year survival rate of 20% [21].